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Hypomorphic Mutations in PGAP2, Encoding
a GPI-Anchor-Remodeling Protein, Cause
Autosomal-Recessive Intellectual Disability
Lars Hansen,1,2,9,* Hasan Tawamie,3,13 Yoshiko Murakami,4,13 Yuan Mang,1,2,13 Shoaib ur Rehman,1,5,13
Rebecca Buchert,3 Stefanie Schaffer,11 Safia Muhammad,12 Mads Bak,1,2 Markus M. No¨then,6,7,8
Eric P. Bennett,9,10 Yusuke Maeda,4 Michael Aigner,11 Andre´ Reis,3 Taroh Kinoshita,4 Niels Tommerup,1,2
Shahid Mahmood Baig,5 and Rami Abou Jamra3,*
PGAP2 encodes a protein involved in remodeling the glycosylphosphatidylinositol (GPI) anchor in the Golgi apparatus. After synthesis
in the endoplasmic reticulum (ER), GPI anchors are transferred to the proteins and are remodeled while transported through the Golgi
to the cell membrane. Germline mutations in six genes (PIGA, PIGL, PIGM, PIGV, PIGN, and PIGO) in the ER-located part of the GPI-
anchor-biosynthesis pathway have been reported, and all are associated with phenotypes extending from malformation and lethality
to severe intellectual disability, epilepsy, minor dysmorphisms, and elevated alkaline phosphatase (ALP). We performed autozygosity
mapping and ultra-deep sequencing followed by stringent filtering and identified two homozygous PGAP2 alterations, p.Tyr99Cys
and p.Arg177Pro, in seven offspring with nonspecific autosomal-recessive intellectual disability from two consanguineous families.
Rescue experiments with the altered proteins in PGAP2-deficient Chinese hamster ovary cell lines showed less expression of cell-surface
GPI-anchored proteins DAF and CD59 than of the wild-type protein, substantiating the pathogenicity of the identified alterations.
Furthermore, we observed a full rescue when we used strong promoters before the mutant cDNAs, suggesting a hypomorphic effect
of the mutations.We report on alterations in the Golgi-located part of the GPI-anchor-biosynthesis pathway and extend the phenotypic
spectrum of the GPI-anchor deficiencies to isolated intellectual disability with elevated ALP. GPI-anchor deficiencies can be interpreted
within the concept of a disease family, and we propose that the severity of the phenotype is dependent on the location of the altered
protein in the biosynthesis chain.Introduction
Posttranslational modification of proteins by the addition
of glycosylphosphatidylinositol (GPI) anchors to the C
termini is well conserved in eukaryotes. GPI anchors func-
tion as sorting signals for the transport of GPI-anchored
proteins (GPI-APs) in the secretory and endocytic path-
ways, and they enable anchoring of the GPI-APs in the
cell-membrane rafts.1 The GPI-anchor-biosynthesis path-
way involves over 20 different gene products (Figure S1,
available online). After synthesis, GPI anchors are trans-
ferred to the proteins in the endoplasmic reticulum (ER)
and are further remodeled by the elimination of acylphos-
phate and ethanolaminephosphate chains. GPI-APs are
then transported from the ER to the plasma membrane
through the Golgi apparatus. In the Golgi apparatus,
fatty-acid remodeling of the GPI anchor occurs; an unsatu-
rated fatty acid is removed by PGAP3, and a saturated fatty
acid is transferred back, most likely by the noncatalytic1Wilhelm Johannsen Centre for Functional Genome Research, The Panum Inst
Denmark; 2Department of Cellular and Molecular Medicine, University of Cop
Human Genetics, University of Erlangen-Nuremberg, Schwabachanlage 10,
World Premier International Immunology Frontier Research Center, Osaka Un
Genetics Laboratory, Health Biotechnology Division, National Institute for Bi
Applied Sciences, 38000 Faisalabad, Pakistan; 6Institute of Human Genetics
7Life and Brain Center, University of Bonn, Sigmund-Freud-Strasse 25, 53127 B
sity of Bonn, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany; 9Copenhage
Blegdamsvej 3B, DK-2200 Copenhagen N, Denmark; 10Department of Odont
N, Denmark; 11Medical Clinic 5, Haematology and Internist Oncology, Univ
12Praxis for Pediatrics and Support for Children with Special Needs, Lattakia,
13These authors contributed equally to this work
*Correspondence: lah@sund.ku.dk (L.H.), rami.aboujamra@uk-erlangen.de (R.
http://dx.doi.org/10.1016/j.ajhg.2013.03.008. 2013 by The American Societ
The Amprotein PGAP2 and presumably also by an uncharacterized
acyltransferase given that PGAP2 itself does not resemble
other acyltransferases (Figure S1).2,3
The GPI-anchor deficiencies represent a subgroup of
congenital disorders of glycosylation.4 Germline muta-
tions in six genes encoding proteins in the ER-located
part of the GPI-anchor-biosynthesis pathway are known:
those in PIGA (MIM 311770), PIGL (MIM 605947), PIGM
(MIM 610273), PIGV (MIM 610274), PIGN (MIM
606097), and PIGO (MIM 614730) (Figure S1 and Table
1).5–8,10,11 Phenotypes of PIGA, PIGL, and PIGNmutations
resulting in protein modification are associated with gross
malformations and in some instances are even lethal.5,6,10
Mutations further downstream of the pathway in PIGVand
PIGO lead to intellectual disability, hyperphosphatasia,
epilepsy, and minor dysmorphisms.8,11 All mutations are
recessive with residual protein function, and it seems
that complete deficiency in GPI-anchor biosynthesis is
incompatible with life.12 A single reported mutation in aitute, University of Copenhagen, Blegdamsvej 3B, DK-2200 Copenhagen N,
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Table 1. Mutations in Genes Involved in the GPI-Anchor-Biosynthesis Pathway
Gene (RefSeq) Protein Function Disease Phenotype Mutation Consequence Origin Reference
PIGA (NM_002641.3) GPI-GlcNAc transferase MCAHS2
(MIM 300868)
multiple congenital anomalies
involving cleft palate, neonatal
seizures, CNS structural
malformations, and other
anomalies
c.[1234C>T];[1234C>T] p.[Arg412*];[Arg412*] unknown Johnston et al.5
PIGL (NM_004278.3) GlcNAc-PI
de-N-acetylase
CHIME syndrome
(MIM 280000)
coloboma, congenital heart
disease, ichthyosiform
dermatosis, mental retardation,
and ear anomalies
c.[274delC];[500T>C]
c.[500T>C];[652C>T]
c.[500T>C];[?]
c.[427–1G>A];[500T>C]
c.[500T>C]; deletion
p.[Leu92Phefs*15];[Leu167Pro]
p.[Leu167Pro];[Gln218*]
p.[Leu167Pro];[?]
p.[ex skip];[Leu167Pro]
p.Leu167Pro
unknown Ng et al.6
PIGM (NM_145167.2) alpha1-4 mannosyl-
transferase I
autosomal-recessive
GPI-anchor deficiency
(MIM 610293)
portal and hepatic vein
thrombosis in early childhood
and seizures
c.[–270C>G];[–270C>G] promoter Middle Eastern,
Turkish
Almeida et al.7
PIGV (NM_017837.3) alpha1-6 mannosyl-
transferase II
HPMRS1
(MIM 239300)
intellectual disability,
hyperphosphatasia, distinct facial
gestalt, seizures, brachytelephalangy
c.[1022C>A];[1022C>A]
c.[1022C>A];[1154A>C]
c.[766C>A];[766C>A]
p.[Ala341Glu];[Ala341Glu]
p.[Ala341Glu];[His385Pro]
p.[Gln256Lys];[Gln256Lys]
unknown Krawitz et al.8
c.[467G>A];[1022C>A]
c.[1022C>A];[1022C>A]
p.[Cys156Tyr];[ Ala341Glu]
p.[Ala341Glu];[ Ala341Glu]
European Horn et al.9
PIGN (NM_012327.5) EtNP
transferase I
MCAHS1
(MIM 614080)
multiple congenital anomalies,
hypotonia, seizures
c.[2126G>A];[2126G>A] p.[Arg709Gln];[Arg709Gln] Israeli Arab Maydan et al.,10
PIGO (NM_032634.3) EtNP
transferase III
HPMRS2
(MIM 614749)
intellectual disability,
hyperphosphatasia, distinct facial
gestalt, seizures, brachytelephalangy
c.[2869C>T];[2361dup]
c.[2869C>T];[3069þ5G>A]
p.[Leu957Phe];[Thr788Hisfs*5]
p.[Leu957Phe];[Val952Aspfs*24]
European Krawitz et al.,11
PGAP2
(NM_001256240.1)
lyso-GPI-AP
acyltransferase
(noncatalytic)
MRT17
(MIM 614207)
severe intellectual disability,
hyperphosphatasia, absence
seizures
c.[296A>G];[296A>G]
c.[530G>C];[530G>C]
p.[Tyr99Cys];[Tyr99Cys]
p.[Arg177Pro];[Arg177Pro]
Syrian
Pakistani
present study
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Figure 1. Affected Children of Family
MR043
The three affected individuals with PGAP2
mutations; there are no major dysmor-
phisms or syndromic gestalt.regulatory element of PIGM leads to a different phenotype
of portal and hepatic vein thrombosis and epilepsy.7
We recently reported genetic mapping in a large group of
families affected by nonspecific autosomal-recessive intel-
lectual disability (ARID) without clinical preselection. In
two consanguineous families, we identified overlapping
linkage to chromosomal region 11p15 (see Figure S2).13,14
Here, we report that each family harbors one homozygous
PGAP2 (postglycosylphosphatidylinositol attachment to
proteins factor 2) mutation encoding a protein involved
in the remodeling of theGPI anchor in theGolgi apparatus.
Functional analyses in PGAP2-deficient Chinese hamster
ovary (CHO) cell lines showed reduced activity of the
respective altered proteins and thus confirmed pathoge-
nicity. Our results extend the phenotypic spectrum of the
GPI-anchor deficiencies to isolated intellectual disability
with elevated alkalinephosphatase (ALP).Ourfindings sup-
port the group of GPI-anchor deficiencies within the
concept of a disease family as suggested by Brunner and
van Driel,15 and we hypothesize that the severity of the
phenotype of a GPI-anchor deficiency is dependent on
the location of the altered protein in the synthesis pathway.Subjects and Methods
Families and Clinical Phenotype of the Affected
Members
This study was approved by the Institutional Research Ethics
Committee of the National Institute for Biotechnology and
Genetic Engineering, School of Biotechnology, Quaid-i-Azam
University (Islamabad, Pakistan); by the National Committee on
Health Research Ethics (Copenhagen, Denmark); and by the ethicsThe American Journal of Humancommittees of the University of Bonn and
the University of Erlangen-Nuremberg
(Germany). Informed consent was ob-
tained from all examined persons or their
guardians.
We examined family MR043 at their
residence in northwestern Syria. The
family consists of two branches, MR043a
and MR043b, which have two affected
girls and one affected girl, respectively
(Figure 1 and Figure S2).13 The affected
girls in MR043a were 6 (IV:1) and 4 (IV:2)
years old at the time of examination. Preg-
nancy, delivery, and birth parameters of
both girls were unremarkable. With esti-
mated IQs below 35, both girls have severe
intellectual disability. Their motor devel-
opment is severely delayed, and they
have pronounced muscular weakness and
hypotonia. Both girls have strabismus,and neither of them has epilepsy. Sleep patterns of both girls are
disordered. Metabolic screening (aminoacidopathies and fattyaci-
dopathies) at the University Children’s Hospital in Damascus
revealed no remarkable values. Serum ALP activity was elevated
to 4,455 U/l in IV:1 and 4,375 U/l in VI-2 (the normal range is
up to 837 U/l). Brain computed-tomography (CT) scans revealed
atrophy and increased gyration in both girls. The elder girl (IV:1)
showed signs of Dandy-Walker malformation (MIM 220200). At
the time of examination, she was 101 cm tall (7 cm below the third
percentile) and had a head circumference of 48 cm (1 cm below
the fifth percentile). IV:2 was 100 cm tall (25th percentile) and
had a head circumference of 47 cm (1 cm below the fifth percen-
tile). Their healthy parents also had head circumferences below
the fifth percentile (52 and 53 cm).
The affected girl, IV:4, inMR043bwas 8.5 years old at the time of
examination. During pregnancy, the mother noticed less fetal
movement. Delivery and birth length were unremarkable, but
severe muscular hypotonia was noted in the neonatal period.
Her motor development was severely delayed: she sat at the age
of 5 years and could not walk at the time of examination. She
spoke single words like ‘‘mama’’ and ‘‘papa.’’ Since the age of 7
years, she has had absence epilepsy. Metabolic screening at the
University Children’s Hospital in Damascus revealed no remark-
able values. Serum ALP values were not available. A CT scan
revealed brain atrophy. Muscle biopsy identified muscle atrophy.
At the time of examination, she was 112 cm tall (6 cm below the
third percentile) and had a head circumference of 50 cm (tenth
percentile). Her siblings and parents had low normal head circum-
ferences. She is a social and joyful girl who loves to play with her
siblings and to move to music.
We examined family MR5 at their residence in the district of
Faisalabad Punjab province, Pakistan (Figure S2).14 The prenatal,
perinatal, and postnatal stages of all four affected members were
uneventful. IQ assessments included verbal and motor abilities
evaluated by the Slosson Intelligence Test16 and showed anGenetics 92, 575–583, April 4, 2013 577
average IQ score of 22. None of the affected members has epilepsy.
The affected family members have head circumferences in the
normal range. They are thin but do not show growth retardation.
Dysmorphological, neurological, opthalmological, and otorhino-
laryngological examinations were normal. Structural MRI revealed
unremarkable results. Cytogenetic examination using a high-reso-
lution G-banding technique showed normal karyotypes. Blood
biochemistry of the liver, renal function, electrolyte levels, thyroid
hormone profiles, hematology, chest X-rays, torch profiles, and
echocardiography were, apart from anemia, unremarkable. There
is no information about serum ALP values.Genetic Mapping and Identification of Mutations
Parametric linkage analyses showed overlapping significant LOD
scores between 0.2 and 6.0 Mb at 11p15.5–p15.4 (Figure S2).13,14
Because of the large number of genes in the candidate region,
we performed next-generation sequencing (NGS). For the Pakis-
tani family, MR5, a custom-designed DNA capture array for the
region chr11: 1–6,000,000 (hg19) was purchased fromNimbleGen
(Roche NimbleGen, Madison, WI, USA). A size-fractionated
genomic library was generated with DNA from individual V:6
and enriched for the target region according to the manufacture’s
protocol. The captured DNA was sequenced with an Illumina
Genome Analyzer II platform (Illumina, San Diego, CA, USA),
and reads were aligned to the human reference sequence hg18
with the use of ELAND and Burrows-Wheeler Aligner software.
The data were filtered for known variants on the basis of public
databases (the National Heart, Lung, and Blood Institute [NHLBI]
Exome Sequencing Project [ESP] Exome Variant Server and 1000
Genomes), and homozygous variants were selected as putative
candidates. Finally, the variants were analyzed in silico with
SIFT, PolyPhen-2, and MutationTaster.17–19 PCR and Sanger
sequencing were done according to standard protocols for the
exclusion of technical artifacts and for segregation testing.
DNA from individual IV:1 of family MR043 was enriched with
the SureSelect Human All Exon 50M Kit (Agilent technologies,
Santa Clara, CA, USA) and was paired-end sequenced on a SOLiD
5500 xl instrument (Life Sciences, Santa Clara, CA, USA). Image
analysis and base calling were performed with SOLiD instrument
control software with default parameters. Read alignment was per-
formed with LifeScope 2.5 with default parameters and human
genome assembly hg19 (GRCh37) as a reference. Single-nucleo-
tide variants (SNVs) and small indels were detected with LifeScope,
GATK 2, and SAMtools/BCFtools. After data were integrated from a
variety of public databases, variant annotation was performed
with Annovar.20 Additionally, variants were compared to an in-
house database containing more than 200 sequenced exomes for
the identification of further common variants not present in pub-
lic databanks. Finally, the variants were analyzed in silico with
SIFT, PolyPhen-2, and MutationTaster, and PCR and Sanger
sequencing were done according to standard protocols for the
exclusion of technical artifacts and for segregation testing.Functional Analyses in CHO Cell Lines
The C84 PGAP2-deficient cell line and the pME vector systems are
described by Tashima and colleagues.21 cDNA (RefSeq accession
number NM_001256240) encoding wild-type PGAP2 isoform 8
was amplified from the cDNA library of human hepatoma cell
line Hep3B and subcloned into a pME vector carrying a strong
aSR promoter. pME vectors containing the mutant PGAP2 cDNAs
were made by site-directed mutagenesis with Pfu-Taq DNA578 The American Journal of Human Genetics 92, 575–583, April 4, 2polymerase and DpnI endonuclease (Agilent Technologies,
Horsholm, Denmark) according to standard protocols. Fragments
encoding wild-type and altered PGAP2 were further ligated into
the pTal-vector system with a medium-strength TK promoter
and into the pTA-vector system with a weak TATA-box promoter.
Wild-type and mutant vector constructs were Sanger sequenced
for unwanted mutations before use in the C84 transfection exper-
iments. PGAP2-deficient CHO cells (C84) were transiently trans-
fected with all three promoters and either wild-type or altered
PGAP2 by electroporation. Cells (5 3 106) were suspended in
0.4 ml of Opti-MEM and electroporated with 10 mg each of the
plasmids at 260 V and 960 mF with a Gene Pulser (Bio-Rad, Hercu-
les, CA, USA). Restoration of the surface expression of DAF and
CD59 was assessed 2 days later by cell staining with mouse DAF
(IA10) or CD59 (5H8) antibody followed by a PE-conjugated
anti-mouse IgG antibody and then by flow-cytometry analysis
(BD FACSCanto II, BD Biosciences, Franklin Lakes, NJ, USA)
with Flowjo software (Tommy Digital, Tokyo, Japan). Levels of
PGAP2 in cells were determined by immunoblotting. PGAP2-
band intensities quantified with Image Gauge software were
normalized for band intensities of endogenous GAPDH and for
transfection efficiencies determined by luciferase activities in the
transfected cells.
Lymphoblastoid Cell Lines and Flow Cytometry
Lymphoblastoid cell lines (LCLs) were cultured in RPMI 1640
(GIBCO, Life Technologies, Darmstadt, Germany) supplemented
with 10% fetal calf serum (PAA Biotech, Co¨lbe, Germany) and
other different supplements. Flow-cytometry analysis was per-
formed with the BD FACSCanto II. For detection of relevant sur-
face markers, the fluorochrome-conjugated antibodies DAF-PE
and CD59-FITC (eBioscience, Frankfurt, Germany) were used.
The mean fluorescent intensity (MFI) was used as an assessment
criterion.Results
NGS and the PGAP2 Mutations
NGS of IV:1 from the Syrian family, MR043, after whole-
exome enrichment resulted in an average coverage of
1533. In the linkage region, 108 variants were nonsynon-
ymous or at splice sites, and only two missense variants in
PGAP2 andDNHD1were not annotated, could be validated
with Sanger sequencing, and segregated in the family. In
silico analysis using MutationTaster, PolyPhen-2, and
SIFT predicted that the variant in DNHD1 is tolerated
but that variant c.296A>G (p.Tyr99Cys) (RefSeq NM_
001256240.1) in PGAP2 is pathogenic (Table 2).
NGS of V:6 from the Pakistani family, MR5, after targeted
enrichment of the whole genomic candidate region
resulted in an average coverage of 1423. We identified
7,040 homozygous SNVs in the candidate region. One
hundred and five variants were nonsynonymous or at
splice sites, and only one variant, c.530G>C (p.Arg177Pro)
(RefSeq NM_001256240.1) in PGAP2, could be verified by
Sanger sequencing and segregated in the family (Table 2).
In silico analysis using MutationTaster and PolyPhen-2
predicted that the variant in PGAP2 is pathogenic, whereas
SIFT predicted the variant to be benign.013
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The AmPGAP2 encodes a transmembrane Golgi protein that is
involved in the modification of the lipid moiety of the
GPI anchor before transport to the cell surface (Figure S1
and Figure 2). Human PGAP2 is represented by at least 16
different RNA transcript variants; eight of them encode
different PGAP2 isoforms, and eight are noncoding RNA
(NCBI gene ID 27315). PGAP2 isoform 8 (encoded by tran-
script variant 12) is 254 amino acids long and has more
than 90% homology with other mammalian orthologs
and 44%–57% homology with the zebrafish and Xenopus
tropicalis orthologs (data not shown). The membrane pre-
diction server TMHMM22 predicted that isoform 8 has
five alpha-helix domains embedded in the Golgi mem-
brane and that its N terminus is in the cytoplasm and its
C terminus is in the Golgi lumen. It is supposed that iso-
form 8 is the biologically active form (T. Kinoshita, unpub-
lished data). Substitutions p.Tyr99Cys and p.Arg177Pro are
in the Golgi lumen between TM1 and TM2 and between
TM3 and TM4, respectively (Figure 2).
PGAP2-Deficient CHO Cells Demonstrate Reduced
Activity for the Altered PGAP2 Proteins
PGAP2 was originally cloned by complementation in
PGAP2-deficient mutant CHO cell lines expressing the
marker proteins DAF (also called CD55) and CD59.21 We
used the PGAP2-deficient CHO cell line C84 to analyze
the functional consequences of the p.Tyr99Cys and
p.Arg177Pro alterations. Because C84 cells express the
GPI-anchored marker proteins DAF and CD59 on the cell
surface at very low levels, they were used for expression
studies after transient transfection of the wild-type and
mutant PGAP2 cDNAs subcloned into the expression vec-
tors. Expression of DAF or CD59 on the cell surface after
transient transfection could be monitored by fluores-
cence-activated cell sorting (FACS) as a measurement of
PGAP2 activity. We subcloned transcript variant 12 cDNAs
encodingwild-type and altered isoform 8 into themamma-
lian expression vector under three different promoters: a
strong SRa promoter, a medium-strength TK promoter,
and a weak TATA promoter. When the strong promoter
was used, the immunoblot was able to detect PGAP2 pro-
teins and clearly demonstrated that the p.Tyr99Cys and
p.Arg177Pro alterations and the wild-type PGAP2 were ex-
pressed at similar levels in the C84 cells (Figure 3A). Endog-
enous GAPDH expression was assessed for controlling
loading efficiencies, and a luciferase expression plasmid
was cotransfected for monitoring transfection efficiency.
With the strong SRa promoter, the wild-type and the two
mutant cDNAs fully restored the GPI-AP expression. How-
ever, with the medium TK promoter (Figure 3B) and the
weak TATA box promoter constructs, the FACS analysis
clearly showed that the wild-type constructs fully restored
GPI-AP expression but that the mutant constructs had
significantly decreased activity in restoring the surface
expression (Figure 3B). These results demonstrate that the
p.Tyr99Cys and p.Arg177Pro altered PGAP2 proteins have
significantly low specific activity.erican Journal of Human Genetics 92, 575–583, April 4, 2013 579
AB
C
p.Tyr99Cys
p.Arg177Pro
p.Tyr99Cys p.Arg177Pro
Figure 2. PGAP2 Exon-Intron Structure and PGAP2 Sequence and Structure
(A) The gene structure for the PGAP2 transcript variants 1 and 12. Isoform 1 (transcript variant 1) has a 61 aa insertion (Ala56 to Gly116)
corresponding to an ectopic exon 3. It seems that transcript 12 (isoform 8) is the active one (Y. Murakami, unpublished data). Arrows
denote the mutations.
(B) The alignment of the human PGAP2 isoform 8 shows homology tomammalian, zebrafish, and frog orthologous proteins. The TM1-5
alpha-helix regions (predicted by TMHMM22) are marked by rectangles, and the altered amino acids are denoted (RefSeq accession
numbers NP_001243169.1 [Homo sapiens], NP_001092581.1 [Bos Taurus], NP_446347.1 [Rattus norvegicus], NP_663558.1 [Mus musculus],
NP_001233740.1 [Cricetulus griseus], NP_001106477.1 [Xenopus tropicalis], and NP_001013562.1 [Danio rerio]).
(C) PGAP2 is a transmembrane protein, and the p.Tyr99Cys and p.Arg177Pro alterations are located in the Golgi lumen.FACS of LCLs with Altered PGAP2 Show Same DAF
and CD59 Expression
It has been reported that mutations in genes involved in
PGI-anchor biosynthesis lead to lower expression of GPI-
anchored markers, such as DAF and CD59, in cells of an
affected individual.6,7,10 We performed FACS with LCLs
derived from three homozygous (/) and six heterozy-
gous (þ/) healthy family members and from 15 healthy
volunteers with a confirmed genotype (þ/þ). DAF and
CD59 expression in LCLs derived from healthy donors
showed high individual variances. The MFI for DAF
and CD59 was 12,267 (6,52222,105) and 31,040
(21,518–53,291), respectively. Cells from heterozygous or
homozygous LCLs showed no significant difference in
the distribution of DAF and CD59 expression (p > 0.2),
although mean MFIs were seen to be somewhat lower in
the homozygous group of individuals (11,326 and 30,018
for DAF and CD59, respectively, Figure S3).Discussion
We investigated two unrelated consanguineous ARID-
affected families sharing the overlapping loci MRT17 and
MRT21.13,14 NGS identified in each family one homozy-
gous missense variant in PGAP2 (Table 2). We considered
both variants to be interesting candidate mutations
because they are not annotated and affect conserved580 The American Journal of Human Genetics 92, 575–583, April 4, 2amino acids. Several prediction programs classified them
as pathogenic. PGAP2 encodes a protein in the biosyn-
thesis pathway of the GPI anchor;1 this protein probably
has five transmembrane alpha-helix domains and is
located in the Golgi apparatus (Figure 2). Changing the
charged and strongly hydrophobic arginine to the
nonpolar and weakly hydrophobic proline (p.Arg177Pro)
and changing the hydrophobic tyrosine to the hydrophilic
cysteine (p.Tyr99Cys) in the Golgi lumen suggest a change
in the secondary and tertiary structures of the protein and
might disturb protein folding. It is also tempting to specu-
late that the PGAP2 interaction with a yet unidentified
putative acyltransferase is disturbed.
To substantiate our results, we performed in vitro func-
tional analyses in CHO cell lines. For both mutations, we
showed reduced expression activity of cell-surface proteins
DAF andCD59 after transient transfection of C84 cells with
mutant constructs. The CHO rescue experiments clearly
demonstrated reduced activity for both PGAP2 alterations
and restoration of GPI-AP expression by the wild-type pro-
tein (Figure3). These functional experiments showreduced,
but not eliminated, PGAP2 activity. A possible consequence
of reduced PGAP2 activity might be interference with
the export and anchoring of the immature GPI-APs in the
cell-membrane rafts. If the immature GPI-APs without the
second saturated fatty acid are transported to the cell sur-
face, the stability of the integration into the cell membrane
might be reduced as a result of only the fatty acyl chain and013
AB
Figure 3. Results of Functional Analyses in CHO Cells
cDNAs encoding PGAP2 isoform 8were subcloned into the vectors under promoters of different strengths and were expressed in PGAP2-
deficient CHO cells.
(A) Immunoblot of cell lysates isolated with the strong SRa promoter after 2 days of expression showed similar levels of wild-type (lane 1)
and altered (lane 2) PGAP2 proteins; an empty-vector construct did not express the protein (lane 3). The protein levels were normalized
(levels are shown underneath the blot) with the intensities of GAPDH expression shown at the left part of the blots.
(B) Expression of the DAF andCD59 cell-surface proteins after transient transfectionwasmonitored by FACS as ameasurement of PGAP2
activities and is shown for the various promoter constructs. The left panel shows the p.Tyr99Cys alteration, and the right panel shows
the p.Arg177Pro alteration. Under the strong SRa promoter, both altered proteins restore the cell-surface expression of DAF and CD59,
suggesting a hypomorphic alteration. Expression under the weak promoters TK and TATA-box shows reduced activity of altered PGAP2
(see Results and Discussion for details).the consequence is release from the cell surface. In pulse-
chase experiments, Tashima and colleagues showed that
the lysoform GPI-APs in PGAP2-deficient CHO cells are
transported to the cell surface and most likely outside of
the rafts and are thereafter released to the medium.21 The
decreased GPI-AP surface expression seen for the PGAP2 al-
terations in the C84 cells might be caused by the release of
those proteins into themedium. The reduced, but not com-The Amplete lack of, cell-surface-expressed GPI-APs suggests hypo-
morphic PGAP2 mutations. Results of FACS of LCLs from
affected individuals showed no differences in the expres-
sion of the cell-surface markers DAF and CD59, which
further supports a hypomorphic effect of the mutation.
Because mutations in PIGA, PIGO, and PIGV are associ-
ated with hyperphosphatasia,5,8,11 we retrospectively
measured the ALP in the available affected members (IV:1erican Journal of Human Genetics 92, 575–583, April 4, 2013 581
and IV:2 from family MR043) and found an elevation of
more than five times its normal level. Thus, we extend
the phenotypic spectrum of GPI-anchor deficiencies to
isolated intellectual disability with elevated ALP.
We think that alterations in various members of the
GPI-anchor pathway represent an overlapping disease
family as discussed by Brunner and van Driel.15 In defi-
ciencies of GPI-anchor proteins, we observe a relation be-
tween the location in the pathway of the deficient protein
and the severity of the phenotype. Mutations in PGAP2 at
the final step of GPI-anchor remodeling cause severe intel-
lectual disability and elevated ALP, and mutations in PIGO
and PIGV, upstream of PGAP2, are also associated with epi-
lepsy, brachydactyly, and facial dysmorphism. Mutations
in PIGA, PIGL, and PIGN, which encode proteins at the
beginning and middle steps of the biosynthesis of the GPI
anchor, have a more severe phenotype: malformations
and even lethality. Furthermore, we observed that com-
pared to wild-type cells, those with mutations in PIGL,
PIGN, and PIGM showed reduced expression of GPI-APs
(e.g.,DAF,CD59,andCD24)on thecell surface;6,7,10howev-
er, expression of DAF and CD59 did not show differences
between cell lines from our affected individuals and cell
lines with mutations in PIGO and PIGV (P.M. Krawitz, per-
sonal communication). It is thuspossible that in this disease
group there is a phenotypic gradient from severe at the
beginning of the biosynthesis pathway to mild toward the
end of the pathway; i.e., the remodeling steps of theGPI an-
chor. We cannot exclude that the phenotype is dependent
on the kind of mutation, e.g., the regulating mutation in
PIGM leads to a fullydifferentphenotype.At this earlyphase
ofdeciphering thephenotypic spectrumassociatedwith the
GPI-anchor-biosynthesis pathway, this hypothesis needs
validation with larger numbers of well-characterized cases.
In conclusion, we have shown that hypomorphic
mutations in PGAP2 lead to severe intellectual disability
with elevated ALP andno obviousmalformations. This rep-
resents a defect in the GPI-anchor-biosynthesis step that
takes place in the Golgi and involves the remodeling of the
anchors, and it expands the phenotypic spectrum of GPI-
anchor deficiencies to isolated intellectual disability.Supplemental Data
Supplemental Data include three figures and can be found with
this article online at http://www.cell.com/AJHG.Acknowledgments
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